Soligenix announced that new supportive trial data for HyBryte in the treatment of cutaneous T-cell lymphoma will be presented at the United States Cutaneous Lymphoma Consortium Workshop on March 26, 2026. The presentations will highlight positive results from a long-term treatment study and a comparative analysis versus Valchlor, supporting HyBryte's potential as a therapeutic option for CTCL.
This development is significant for patients with cutaneous T-cell lymphoma, a rare form of cancer that affects the skin and currently has limited treatment options. The presentation of new data at a major dermatology workshop ahead of the American Academy of Dermatology Annual Meeting indicates growing scientific interest and validation of HyBryte's clinical profile. For the medical community, comparative data against Valchlor provides crucial information for treatment decision-making, potentially offering physicians an alternative therapeutic approach with a different mechanism of action.
HyBryte represents a novel photodynamic therapy utilizing safe visible light for the treatment of CTCL. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. The therapy's expansion into other conditions, including psoriasis through synthetic hypericin (SGX302), demonstrates the platform's broader potential in dermatology and inflammatory diseases.
The implications of this announcement extend beyond immediate clinical applications. Positive long-term data can influence treatment guidelines, insurance coverage decisions, and patient access to innovative therapies. For the pharmaceutical industry, successful development of treatments for rare diseases like CTCL represents both a medical advancement and a viable business model for addressing unmet needs in smaller patient populations.
Soligenix's broader development pipeline includes additional programs in its Specialized BioTherapeutics business segment, such as dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer, and SGX945 in Behcet's Disease. The company's Public Health Solutions business segment includes vaccine development programs incorporating proprietary heat stabilization platform technology known as ThermoVax, supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases.
Investors and stakeholders can find additional information in the company's newsroom at https://ibn.fm/SNGX. The presentation of new HyBryte data represents a milestone in the therapy's development pathway and provides important clinical information for healthcare providers treating patients with cutaneous T-cell lymphoma.
